::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

SAFETY AND EFFICACY OF ACARBOSE IN COMBINATION WITH INSULIN GLARGINE IN TREATMENT OF ELDER DIABETIC PATIENTS

AUTHORS:

Sumbal Farooq, Maham Tauqeer, Armghan Aqdus

ABSTRACT:

Objective: To interrogate the clinical safety and effectiveness of insulin glargine in combination with acarbose for the treatment of diabetes in the patients with elder age. Methodology: Total 140 patients suffering from diabetes who obtained treatment from January 2019 to January 2020 at DHQ Teaching Hospital Gujranwala got selected and the separation of these patients was carried out in Control Group (CG) and Observation Group (OG) with 70 patients in each group with the help of random number method. We treated the patients of control group with the help of insulin glargine, whereas the treatment of the patients of Observation Group was carried out with the help of insulin glargine in combination with acarbose. We performed the comparison about the therapeutic impact, improvement of QoL (Quality of Life) and adverse reactions between the patients of both groups. Results: After the completion of therapy, FBG (Fasting Blood Glucose), 2h PBG (Postprandial Blood Glucose) and HbA1c (Glycosylated Hemoglobin) of the patients of both groups were less before the start of the treatment and the degree of decrease was much larger in the patients of Observation Group as compared to the patients of control group (P < 0.050). The duration required for the blood glucose to reach at standard level and daily usage of insulin of the patients of Observation Group were much lower than the patients of control group and this difference was significant statistically (P < 0.050). Scores of SF-36 scales of the patients of Observation Group were much better as compared to the patients of control group and this difference was also significant statistically (P < 0.050). We found no statistical difference in the prevalence rate of adverse reactions between the patients of both groups (P >0.050). Conclusion: The combine treatment of insulin Glargine & Acarbose can significantly handle the glucose level of blood in the diabetics of elder age, improves the bio-chemical indicators and promote the QoL. KEYWORDS: Diabetics, Glargine, Insulin, Acarbose, Therapeutic, Fasting Blood Glucose, Postprandial Blood Glucose.